Corvus Pharmaceuticals, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Corvus Pharmaceuticals, Inc. (CRVS) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 14.03 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-03-12
- Corvus Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2021-03-31 was 6.22M shares, a 8.80% increase year-over-year.
- Corvus Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2020-09-30 was 5.39M shares, a 31.67% increase year-over-year.
- Corvus Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2020-06-30 was 5.56M shares, a 33.37% increase year-over-year.
- Corvus Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2020-03-31 was 5.72M shares, a 40.61% increase year-over-year.
- Corvus Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 14.03M shares, a 40.84% decline from fiscal 2024.
- Corvus Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 23.71M shares, a 156.52% increase from fiscal 2023.
- Corvus Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 9.24M shares, a 31.94% increase from fiscal 2022.
- Corvus Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 7.01M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 11 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | 14.03M shares 10-K · filed 2026-03-12 | |||||
| 2024-12-31 | 23.71M shares 10-K · filed 2026-03-12 | |||||
| 2023-12-31 | 9.24M shares 10-K · filed 2026-03-12 | |||||
| 2022-12-31 | 7.01M shares 10-K · filed 2025-03-25 | |||||
| 2021-03-31 | 6.22M shares 10-Q · filed 2021-04-29 | |||||
| 2020-12-31 | 6.66M shares 10-K · filed 2021-03-25 | |||||
| 2020-09-30 | 5.39M shares 10-Q · filed 2020-10-29 | 5.39M shares 10-Q · filed 2020-10-29 | ||||
| 2020-06-30 | 5.56M shares 10-Q · filed 2020-07-30 | 5.56M shares 10-Q · filed 2020-07-30 | ||||
| 2020-03-31 | 5.72M shares 10-Q · filed 2021-04-29 | |||||
| 2019-12-31 | 5.64M shares 10-K · filed 2021-03-25 | |||||
| 2019-09-30 | 4.09M shares 10-Q · filed 2020-10-29 | 4.09M shares 10-Q · filed 2020-10-29 | ||||
| 2019-06-30 | 4.17M shares 10-Q · filed 2020-07-30 | 4.17M shares 10-Q · filed 2020-07-30 | ||||
| 2019-03-31 | 4.07M shares 10-Q · filed 2020-04-30 | |||||
| 2018-12-31 | 3.82M shares 10-K · filed 2021-03-25 | |||||
| 2018-09-30 | 2.91M shares 10-Q · filed 2019-10-29 | 2.91M shares 10-Q · filed 2019-10-29 | ||||
| 2018-06-30 | 3.19M shares 10-Q · filed 2019-08-01 | 3.19M shares 10-Q · filed 2019-08-01 | ||||
| 2018-03-31 | 3.25M shares 10-Q · filed 2019-05-09 | |||||
| 2017-12-31 | 3.33M shares 10-K · filed 2020-03-09 | |||||
| 2017-09-30 | 2.82M shares 10-Q · filed 2018-11-01 | 2.82M shares 10-Q · filed 2018-11-01 | ||||
| 2017-06-30 | 2.91M shares 10-Q · filed 2018-08-02 | 2.91M shares 10-Q · filed 2018-08-02 | ||||
| 2017-03-31 | 2.90M shares 10-Q · filed 2018-05-03 | |||||
| 2016-12-31 | 2.96M shares 10-K · filed 2019-03-07 | |||||
| 2016-09-30 | 2.74M shares 10-Q · filed 2016-11-03 | 2.74M shares 10-Q · filed 2017-11-02 | ||||
| 2016-06-30 | 2.80M shares 10-Q · filed 2016-08-04 | 2.80M shares 10-Q · filed 2017-08-03 | ||||
| 2016-03-31 | 2.63M shares 10-Q · filed 2017-05-04 | 2.67M shares 10-Q · filed 2016-05-05 | ||||
| 2015-12-31 | 15.98M shares 10-K · filed 2018-03-01 | |||||
| 2015-09-30 | 15.77M shares 10-Q · filed 2016-11-03 | 15.77M shares 10-Q · filed 2016-11-03 | ||||
| 2015-06-30 | 9.91M shares 10-Q · filed 2016-08-04 | 9.91M shares 10-Q · filed 2016-08-04 | ||||
| 2015-03-31 | 5.29M shares 10-Q · filed 2016-05-05 | |||||
| 2014-12-31 | 4.20M shares 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |